Mesoblast has about 320 million outstanding shares. They have a $1.85 billion market because they are in Australia and have the backing of TEVA. They are well behind Bioheart in commercializing in the US. So what's your point?
How many shares are authorized? Sorry if this question had been answered already. I thought that shares increases had to be approved by the board of directors as well as the common shareholders. Any additional info surrounding this topic would be great.